Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Dushyant V. Sahani, M.D.

Co-Author

This page shows the publications co-authored by Dushyant Sahani and Rakesh Jain.
Connection Strength

1.404
  1. Reply to Ciccolini et al.: Using mathematical modeling to predict response to antiangiogenic therapy in cancer patients. Proc Natl Acad Sci U S A. 2015 Jul 07; 112(27):E3454.
    View in: PubMed
    Score: 0.155
  2. Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. Proc Natl Acad Sci U S A. 2015 Feb 03; 112(5):1547-52.
    View in: PubMed
    Score: 0.151
  3. Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy. J Hematol Oncol. 2013 Jul 10; 6:51.
    View in: PubMed
    Score: 0.136
  4. Phase II trial of carboplatin, abraxane, and bevacizumab in NSCLC. J Clin Oncol. 2011 May 20; 29(15_suppl):e18016.
    View in: PubMed
    Score: 0.117
  5. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol. 2011 May; 8(5):292-301.
    View in: PubMed
    Score: 0.116
  6. Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies. Cancer J. 2009 Jul-Aug; 15(4):263-8.
    View in: PubMed
    Score: 0.103
  7. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol. 2009 Jun; 6(6):327-38.
    View in: PubMed
    Score: 0.102
  8. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol. 2009 Jun 20; 27(18):3020-6.
    View in: PubMed
    Score: 0.102
  9. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009 Jun 20; 27(18):3027-35.
    View in: PubMed
    Score: 0.102
  10. Sunitinib monotherapy in patients with advanced hepatocellular carcinoma (HCC): Insights from a multidisciplinary phase II study. J Clin Oncol. 2008 May 20; 26(15_suppl):4521.
    View in: PubMed
    Score: 0.095
  11. Phase I study of neoadjuvant bevacizumab, 5-fluorouracil, and radiation therapy followed by surgery for patients with primary rectal cancer. J Clin Oncol. 2004 Jul 15; 22(14_suppl):3589.
    View in: PubMed
    Score: 0.073
  12. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004 Feb; 10(2):145-7.
    View in: PubMed
    Score: 0.071
  13. Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study. Clin Cancer Res. 2013 Mar 15; 19(6):1557-66.
    View in: PubMed
    Score: 0.033
  14. Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):1081-90.
    View in: PubMed
    Score: 0.028
  15. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol. 2005 Nov 01; 23(31):8136-9.
    View in: PubMed
    Score: 0.020
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.